177 related articles for article (PubMed ID: 22172384)
1. Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab.
Jang BS; Lee SM; Kim HS; Shin IS; Razjouyan F; Wang S; Yao Z; Pastan I; Dreher MR; Paik CH
Nucl Med Biol; 2012 May; 39(4):472-83. PubMed ID: 22172384
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
3. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.
Wang S; Shin IS; Hancock H; Jang BS; Kim HS; Lee SM; Zderic V; Frenkel V; Pastan I; Paik CH; Dreher MR
J Control Release; 2012 Aug; 162(1):218-24. PubMed ID: 22732476
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
5. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
6. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
[TBL] [Abstract][Full Text] [Related]
7. Combined modality radioimmunotherapy. Promise and peril.
Burke PA; DeNardo SJ; Miers LA; Kukis DL; DeNardo GL
Cancer; 2002 Feb; 94(4 Suppl):1320-31. PubMed ID: 11877763
[TBL] [Abstract][Full Text] [Related]
8. Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice.
Khaibullina A; Jang BS; Sun H; Le N; Yu S; Frenkel V; Carrasquillo JA; Pastan I; Li KC; Paik CH
J Nucl Med; 2008 Feb; 49(2):295-302. PubMed ID: 18199622
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Saï-Maurel C; Campion L; Faivre-Chauvet A; Mirallié E; Chérel M; Supiot S; Barbet J; Chatal JF; Thédrez P
Mol Cancer Ther; 2002 Feb; 1(4):267-74. PubMed ID: 12467222
[TBL] [Abstract][Full Text] [Related]
10. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Gold DV; Modrak DE; Schutsky K; Cardillo TM
Int J Cancer; 2004 Apr; 109(4):618-26. PubMed ID: 14991585
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
[TBL] [Abstract][Full Text] [Related]
14. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
Shah DK; Veith J; Bernacki RJ; Balthasar JP
Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of pancreatic cancer xenograft with
Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T; Higashi T
World J Gastroenterol; 2017 Nov; 23(42):7551-7562. PubMed ID: 29204055
[TBL] [Abstract][Full Text] [Related]
17. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Gold DV; Schutsky K; Modrak D; Cardillo TM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
20. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
